Effect of using azithromycin and sodium stibogluconate in the treatment of cutaneous leishmaniasis


  • Lamiaa Hussien Gomaa Pediatrics specialist, Egyptian ministry of health, Egypt
  • Menatalla Saber Gomaa Freelance dermatologists, Egypt
  • Ali Husayn Alhadad Laboratory Technology Department, Higher Institute of Medical Sciences and Technologies, Bani Waleed, Libya


Cutaneous leishmaniasis, intra-lesional sodium stibogluconate, azithromycin.


This study was conducted on 50 patients with cutaneous leishmaniasis in Libya, and the patients were divided into two groups. Group A received sodium stibogluconate only by injection into the infection area and group B received combination therapy of sodium stibogluconate and azithromycin 500 mg orally. Follow-up was done to observe the recovery of the cases in the sixth week and at the end of the eighth week of treatment. The majority of the infections in patients were nodular (60%) and ulceration (40 %). After 6th week treatment, in group A, complete healing of the infection was found in 11(44%) patients and very good response found in 6(24%) patients, while inn group B, complete healing was found in18 (75%) patients and very good response was found in 4 (16%). It could be concluded that, oral azithromycin in combination with intral-lesional sodium stibogluconate could achieve earlier healing of the lesion and less possibility of resistant cases.


WHO (2017): World Health Organization, Regional Office for the Eastern Mediterranean; 1-52.

Simon L. Croft1, Sundar S, Fairlamb AH. (2006): Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev; 1: 111-126.

WHO, World Health Organization (2010): Control of the leishmaniases: WHO technical report series no. 949. Geneva.

Reedijk SH, Schallig HD. (2015): Cutaneous leishmaniasis: recent developments in diagnosis and management; 16:99-109.

Bennis I, Severine T, Filali H, Brouwere VD,Shihabi H, Boelaert M.(2017): Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Errachidia province, Morocco. Infect Dis of Pover J.; 6: 44-53.

Piscopo TV and Azzopardi CM. (2007): Leishmaniasis. Post-grad Med J. 83: 649-657.

Brito NC, Rabello A, Cota GF. (2017): Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS ONE; 9: e0184777.

Khatami A, Firooz A, Gorouhi F, and Dowlati Y. (2007): Treatment of acute old world cutaneous eishmaniasis: A systematic review of the randomized controlled trials. J Am Acad Dermatol; 57: 335.e1-335.e29.

Arevalo I, Ward B, Miller R, Meng T. (2001): Successful treatment of drug-resistant cutaneous Leishmaniasis in humans by Use of Imiquimod, an Immunomodulator. Clini Infect Dis. 33:1847–1851.

Al-Natour SH. (2009): Update in the treatment of cutaneous leishmaniasis. J Family Comm Med; 16: 41–47.

Prata A, Silva-Vergara ML, Costa L. (2003): Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical; 1:65-69.

Amer EI, Eissa MM, Mossallam SF. (2016): Oral azithromycin versus its combination with miltefosine for the treatment of experimental. Old World cutaneous leishmaniasis. J Parasit Dis; 2: 475-484.

Oliveira-Silva F, Morais-Teixeira E, Rabello A. (2008): Antileishmanial Activity of Azithromycin Against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am. J. Trop. Med. Hyg ; 5: 745–749



How to Cite

Lamiaa Hussien Gomaa, Menatalla Saber Gomaa, & Ali Husayn Alhadad. (2024). Effect of using azithromycin and sodium stibogluconate in the treatment of cutaneous leishmaniasis. Libyan Journal of Medical and Applied Sciences, 2(1), 28–31. Retrieved from https://ljmas.com/index.php/journal/article/view/13



Life Sciences